Listar por autor "Idilman, R."
Mostrando ítems 1-7 de 7
-
Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with on-treatment parameters?
Onder, F. O.; Erhardt, A.; Idilman, R.; Keskin, O.; Dalekos, G. N.; Yalcin, K.; Manns, M. P.; Wedemeyer, H.; Yurdaydin, C. (2012) -
HBeAg-positive hepatitis delta: Virological patterns and clinical long-term outcome
Heidrich, B.; C. Serrano, B.; Idilman, R.; Kabaçam, G.; Bremer, B.; Raupach, R.; Önder, F. O.; Deterding, K.; Zacher, B. J.; Taranta, A.; Bozkaya, H.; Zachou, K.; Tillmann, H. L.; Bozdayi, A. M.; Manns, M. P.; Yurdaydin, C.; Wedemeyer, H. (2012)Background and Aims: The presence of the hepatitis B virus (HBV)-eAg in patients with hepatitis B is associated with higher HBV replication and with an increased risk to develop liver-related clinical endpoints defined as ... -
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
Papatheodoridis, G. V.; Dalekos, G. N.; Yurdaydin, C.; Buti, M.; Goulis, J.; Arends, P.; Sypsa, V.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Papaioannou, C.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L. A.; Lampertico, P. (2015)Background & Aims: The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear. We evaluated the incidence and predictors of ... -
LONG-TERM FOLLOW-UP AFTER PEG-IFNa2a-BASED THERAPY OF CHRONIC HEPATITIS DELTA
Heidrich, B.; Yurdaydin, C.; Kabacam, G.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Bock, T.; Idilman, R.; Manns, M. P.; Wedemeyer, H. (2013) -
Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF)
Papatheodoridis, G. V.; Dalekos, G. N.; Yurdaydin, C.; Goulis, I.; Arends, P.; Buti, M.; Sypsa, V.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Papaioannou, C.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L.; Lampertico, P. (2013) -
Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta
Kabaçam, G.; Wedemeyer, H.; Savaş, B.; Keskin, O.; Dalekos, G.; Tabak, F.; Idilman, R.; Erhardt, A.; Yalçin, K.; Bozdayi, M. A.; Bozkaya, H.; Manns, M.; Dienes, H.; Yurdaydin, C.; Berg, T.; Böcher, W.; Bohle, H.; Buggisch, P.; Cornberg, M.; Ers̈oz, G.; Feyerabend, S.; Hinrichsen, H.; Manok, M.; Häussinger, D.; Herzog, W.; Hofmann, W. P.; Plein, K.; Hardt, H.; Porst, H.; Mederacke, I.; Rigopoulou, E. I.; Sentürk, H.; Wagner, E. K. V. (2014)Background & Aims: Immunohistochemical assessment of liver tissue in chronic delta hepatitis (CDH) is underinvestigated. Aim of the study was (i) to assess variables associated with hepatitis D antigen (HDAg), hepatitis B ... -
Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF)
Papatheodoridis, G. V.; Dalekos, G. N.; Sypsa, V.; Yurdaydin, C.; Buti, M.; Goulis, I.; Chi, H.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Vlachogiannakos, J.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L.; Lampertico, P. (2014)